948 Extracorporeal shock wave therapy for chronic prostatitis III-a-b

Kulchavenya, E.; Шевченко, С. П.; Brizhatyuk, E.

doi:10.1016/s1569-9056(16)60949-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kulchavenya et al. (2016) reported that the improvement of symptoms in CP/CPPS patients occurred in four‐week follow‐up after receiving Li‐ESWT, and no apparent improvement during the treatment. In addition, our further analysis found that improved patients responded more effectively to pain relief during the early stages of Li‐ESWT (started in the 1st week), whereas changes in urinary symptoms contributed to the improvement of PLS during the later stages (started in the 2nd week), and the decline in IPSS scores suggested that voiding functions (obstruction symptoms and irritation symptoms) were dramatically improved after Li‐ESWT ( p < .05).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety evaluation of low‐intensity extracorporeal shock wave therapy on prostatitis‐like symptoms: An open‐label, single‐arm trial

Jin

Zhang

et al. 2021

Andrologia

View full text Add to dashboard Cite

The present work aims to evaluate the clinical efficacy and safety of low‐intensity extracorporeal shock wave therapy (Li‐ESWT) on patients with prostatitis‐like symptoms (PLS). Patients with PLS were recruited and received four‐week Li‐ESWT (once per week), which was conducted at a frequency of 3 Hz with a preferred energy flow density of 0.25 mJ/mm2. The scores of the National Institute of Health Chronic Prostatitis Symptoms Index (NIH‐CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF‐5), and Visual Analogue Scale (VAS) were recorded to assess the remission of disease in the 0, 1st, 2nd, 3rd, 4th, 5th, 8th and 16th weeks. A decrease of the NIH‐CPSI score ≥6 was regarded as the effectiveness standard of Li‐ESWT. Among 91 enrolled patients, the scores of all validated questionnaires presented significant improvements in the 4th week (p < .05) compared with that in baseline, except for IIEF‐5. The treatment effective rates in the 1st, 2nd, 3rd, 4th, 5th, 8th and 16th weeks were 28.57%, 38.46%, 47.25%, 51.65%, 57.30%, 68.18% and 69.44%, respectively. No pronounced undesirable side effect has occurred. Li‐ESWT is effective and safe in treating PLS. The efficacy can be maintained within three months.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety evaluation of low‐intensity extracorporeal shock wave therapy on prostatitis‐like symptoms: An open‐label, single‐arm trial

Jin

Zhang

et al. 2021

Andrologia

View full text Add to dashboard Cite

show abstract

“…Based on our previously published study, 10 we supposed that the NIH‐CPSI pain domain score would improve at the 12‐week follow‐up by 4.6 points in the once‐weekly group and, based on available data, 13,17 by 5.5 points in the twice‐weekly group compared to baseline. Therefore, a sample size of 21 patients per group would have 80% power to detect a mean difference of 0.9 ± 1 between the two groups with a two‐sided significance level of 0.05.…”

Section: Methodsmentioning

confidence: 99%

Comparing two different low‐intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two‐arm, parallel‐group randomized controlled trial

et al. 2021

View full text Add to dashboard Cite

Background: Despite encouraging results, the optimal low-intensity shockwave therapy (LiST) protocol in patients with chronic prostatitis/chronic pelvic pain syndrome (CPPS) remains unknown. We conducted a two-arm, parallel-group, randomized controlled trial aiming to compare the efficacy and safety of six LiST sessions applied once or twice weekly.Methods: Fifty patients with CP/CPPS type IIIb were randomly assigned to six LiST sessions once (Group A, n = 25) or twice weekly (Group B, n = 25). Both groups followed the same treatment protocol in terms of LiST application, impulses (5000/ session), energy flux density (0.096 mJ/mm 2 ) and frequency (5 Hz). Subsequently, all participants were evaluated at 1 and 3 months after completion of LiST protocol.Results: At the follow-up evaluations, LiST significantly improved the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) total, pain and quality of life scores, as well as the International Index of Erectile Function-Erectile Domain (IIEF-ED) in both groups (p < .001 for all measures). Comparing between the two groups, no significant differences were demonstrated in the NIH-CPSI total, pain, urinary and quality of life scores, as well as in the International Prostate Symptom Score, IIEF-ED, and LiST-induced pain at both follow-up evaluations. Accordingly, no adverse events and no dropouts were observed in both groups. Conclusion:Six sessions of LiST applied once weekly for 6 weeks or twice weekly for 3 weeks seem to be equally safe and effective in patients with CP/CPPS. Nevertheless, further studies are necessary, since LiST gradually gains its place for the management of CP/CPPS.

show abstract

948 Extracorporeal shock wave therapy for chronic prostatitis III-a-b

Cited by 2 publications

References 0 publications

Efficacy and safety evaluation of low‐intensity extracorporeal shock wave therapy on prostatitis‐like symptoms: An open‐label, single‐arm trial

Efficacy and safety evaluation of low‐intensity extracorporeal shock wave therapy on prostatitis‐like symptoms: An open‐label, single‐arm trial

Comparing two different low‐intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two‐arm, parallel‐group randomized controlled trial

Contact Info

Product

Resources

About